These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36336743)

  • 1. Clinical evaluation of nebulized verapamil in out-patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease.
    Fahimi F; Pourdowlat G; Behzadnia N; Mostofi SS; Forough AS; Parto O; Esmaeili A
    Clin Respir J; 2022 Dec; 16(12):802-811. PubMed ID: 36336743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of nebulized verapamil on chronic obstructive pulmonary disease: A randomized and double-blind clinical trial.
    Bozorgmehr R; Edalatifard M; Safavi E; Rahimi B; Ghorbani F; Abtahi H; Amini S; Pourdowlat G
    Clin Respir J; 2020 Apr; 14(4):370-381. PubMed ID: 31900997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Nebulized Verapamil on Oxygenation in Chronic Obstructive Pulmonary Disease (COPD) Patients Admitted to the Intensive Care Unit.
    Pourdowlat G; Alizade Kashani R; Ghorbani F; Baniasadi S; Jamaati H; Farzanegan B
    Tanaffos; 2019 Apr; 18(4):329-337. PubMed ID: 32607114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
    Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E
    Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of glycopyrrolate/eFlow
    Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
    Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
    Chogtu B; Kuriachan S; Magazine R; Shetty KR; Kamath A; George MM; Tripathy A; Kumar DM
    Indian J Pharmacol; 2016; 48(5):503-508. PubMed ID: 27721534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD.
    Hanania NA; Sethi S; Koltun A; Ward JK; Spanton J; Ng D
    Int J Chron Obstruct Pulmon Dis; 2019; 14():117-127. PubMed ID: 30643398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salbutamol Nebulization During Noninvasive Ventilation in Exacerbated Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial.
    Bodet-Contentin L; Guillon A; Boulain T; Frat JP; Garot D; Le Pennec D; Vecellio L; Ehrmann S; Giraudeau B; Tavernier E; Dequin PF
    J Aerosol Med Pulm Drug Deliv; 2019 Jun; 32(3):149-155. PubMed ID: 30589607
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
    Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
    Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
    Devereux G; Cotton S; Barnes P; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; McCormack K; McPherson G; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Trials; 2015 Jun; 16():267. PubMed ID: 26058585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of nebulized levalbuterol in stable COPD.
    Datta D; Vitale A; Lahiri B; ZuWallack R
    Chest; 2003 Sep; 124(3):844-9. PubMed ID: 12970007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients.
    Gross NJ; Nelson HS; Lapidus RJ; Dunn L; Lynn L; Rinehart M; Denis-Mize K;
    Respir Med; 2008 Feb; 102(2):189-97. PubMed ID: 18363201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
    Mahler DA; Waterman LA; Ward J; Gifford AH
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
    Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
    BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.